Last reviewed · How we verify
Prophylactic growth factors; subcutaneous
At a glance
| Generic name | Prophylactic growth factors; subcutaneous |
|---|---|
| Sponsor | Array Biopharma, now a wholly owned subsidiary of Pfizer |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (PHASE2)
- Efficacy and Safety of rhTPO's Prophylactic Treatment of CTIT in Patients With High Risk of Cardiac Injury (PHASE4)
- A Study of ARRY-334543 and Docetaxel in Patients With Advanced Cancer (PHASE1)
- Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer (PHASE2)
- Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |